448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts.

Authors :: Penson, R T
Drew, Y
Jonge, M J A de
Hong, S-H
Park, Y H
Wolfer, A
Brown, J
Ferguson, M
Gore, M E
Alvarez, R H
Source :: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.
Publication Year :: 2018

Subjects :: *POLY(ADP-ribose) polymerase
*OVARIAN cancer
*TUMORS
*CANCER
*IMMUNOGLOBULINS
*PEMBROLIZUMAB

Full Text Access

Tools